ResearcherThe Cancer Institute HospitalActive in the last 2 years
Shoki Sato
Matched on ORCID iD 0000-0002-0727-8967; OpenAlex author ID A5021748750. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 3
- Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
- Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
- Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Co-author DOI 10.1007/s00423-023-02942-0↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Atsushi Oba · 3 shared papers, 2023–2026 · strength 0.54
- Paper Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed… DOI 10.1002/jhbp.70054↗
- Paper Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal r… DOI 10.1007/s00423-023-02942-0↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Yosuke Inoue · 2 shared papers, 2023–2026 · strength 0.38
- Paper Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed… DOI 10.1002/jhbp.70054↗
- Paper Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal r… DOI 10.1007/s00423-023-02942-0↗
- Yoshihiro Ono · 2 shared papers, 2023–2024 · strength 0.34
- Paper Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal r… DOI 10.1007/s00423-023-02942-0↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Hiromichi Ito · 2 shared papers, 2023–2024 · strength 0.34
- Paper Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal r… DOI 10.1007/s00423-023-02942-0↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Yu Takahashi · 2 shared papers, 2023–2024 · strength 0.34
- Paper Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal r… DOI 10.1007/s00423-023-02942-0↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Denys Tsybulskyi · 1 shared paper, 2026 · strength 0.20
- So Yamaki · 1 shared paper, 2026 · strength 0.20
- Sohei Satoi · 1 shared paper, 2026 · strength 0.20
- Teiichi Sugiura · 1 shared paper, 2026 · strength 0.20
- Kenjiro Okada · 1 shared paper, 2026 · strength 0.20
- Ryuta Shintakuya · 1 shared paper, 2026 · strength 0.20
- Masamichi Mizuma · 1 shared paper, 2026 · strength 0.20
- Toshimichi Asano · 1 shared paper, 2026 · strength 0.20
- Daisuke Hashimoto · 1 shared paper, 2026 · strength 0.20
- Kenichiro Uemura · 1 shared paper, 2026 · strength 0.20
- Daisuke Ban · 1 shared paper, 2026 · strength 0.20
- Katsuhisa Ohgi · 1 shared paper, 2026 · strength 0.20
- Nobuhiko Nakagawa · 1 shared paper, 2026 · strength 0.20
- Aistė Gulla · 1 shared paper, 2026 · strength 0.20
- Koetsu Inoue · 1 shared paper, 2026 · strength 0.20
- Michiaki Unno · 1 shared paper, 2026 · strength 0.20
- Satoshi Hirano · 1 shared paper, 2026 · strength 0.20
- Fuyuhiko Motoi · 1 shared paper, 2026 · strength 0.20
- Y. H. Andrew Wu · 1 shared paper, 2023 · strength 0.18
- Tomotaka Kato · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.